Over the last few years, several papers have become available in the literature on both the main hallmarks of Alzheimer's disease (AD) and the several intracellular pathways whose alteration is responsible for its onset and progression. The use of transgenic and nontransgenic animal models has played a key role in achieving such a remarkable amount of preclinical data, allowing researchers to dissect the cellular changes occurring in the AD brain. In addition, the huge amount of preclinical evidence arising from these animal models was necessary for the further clinical development of pharmacological agents capable of interfering with most of the impaired neural pathways in AD patients. In this respect, a significant role is played by the dysfunction of excitatory and inhibitory neurotransmission responsible for the cognitive and behavioral symptoms described in AD patients. The aim of this review is to summarize the main animal models that contributed toward unraveling the pathological changes in neurotransmitter synthesis, release, and receptor binding in AD preclinical studies. The review also provides an updated description of the current pharmacological agents -still under clinical development -acting on the neurotransmitter systems. Behavioural Pharmacology 28:95-111 Copyright
Introduction
Alzheimer's disease (AD) is a chronic and irreversible neurodegenerative disorder and the most common cause of dementia (Querfurth and LaFerla, 2010) . According to the Diagnostic and Statistical Manual of Mental Disorders, 5th ed. (DSM-5) criteria, dementia is classified as a major neurocognitive disorder interfering with both cognitive functions and activities of daily living (American Psychiatric Association, 2013) . The prevalence of dementia, and in particular, of AD, is predicted to increase considerably in the decades to come because of the aging population, lifestyle, and socioeconomic risk factors. A very recent report on the American population estimates an increase of 14% over the next 10 years in the number of the individuals affected, a major healthcare concern that will have a remarkable influence on society, financial cost, families, and caregivers (Alzheimer's Association, 2016). Moreover, the incidence of elderly individuals developing dementia and AD is predicted to double by 2050 (Hebert et al., 2001) : in 2016, the number of AD cases has been estimated to be around 476 000 in the USA alone (Alzheimer's Association, 2016).
The histopathological hallmarks of AD are characterized by cerebral deposits of neurofibrillary tangles (NFT) composed of hyperphosphorylated microtubule-associated tau protein and by neuritic plaques consisting of assembled forms of amyloid-β peptide (Aβ) (Hardy and Selkoe, 2002) . In the last decade, new scientific evidence from preclinical and clinical studies has renewed this classical amyloid hypothesis. In view of this, it has been suggested that an imbalance between the production and clearance of soluble forms of Aβ peptides might be an early and initiating pathological feature that triggers the synaptic dysfunction and cognitive decline in AD (Selkoe and Hardy, 2016) . The downstream molecular and pathophysiological pathways driving Aβ or tau toxicity include a widespread neurodegeneration, synaptic loss, and dysfunction of forebrain cholinergic neuronal activity that progressively leads to subsequent neurotransmitter network failure. Experimental studies have mainly targeted the cholinergic and the glutamatergic systems as possible candidates in the drug development for AD (for a review, see Mancuso et al., 2011) . Indeed, clinical studies have shown that the use of acetylcholinesterase inhibitors (AChE-I), which are drugs that prevent acetylcholine (ACh) degradation, is accompanied by an increased synaptic activity and improvement of memory loss (Musial et al., 2007; Greenberg et al., 2013) . Moreover, it has been reported that, by preventing calcium-dependent neurotoxicity, N-methyl-D-aspartate (NMDA) receptor antagonists exert weak effects on cognitive dysfunctions (Cosman et al., 2007) . However, the clinical benefit of these pharmacological treatments is limited in time because of the continuous and progressive neurodegenerative cascade that, in turn, leads to neuronal loss in a time-dependent manner (Thomas and Grossberg, 2009; Lundkvist et al., 2014) .
Despite the considerable progress made by researchers to better elucidate the underpinning pathways involved in AD pathology and the efforts to develop an effective therapeutic strategy, AD remains a major healthcare concern. In this respect, a variable onset of memory impairment along with overlapping noncognitive symptoms, inclusion criteria, and the use of add-on drugs, dose-ranging schedule, and duration of treatment regimen are only some of the variables that render difficult the search for effective disease-modifying therapeutic strategies in clinical trials. Indeed, AD-like phenotypes take decades to develop in humans, and starting clinical trials when the disease is too advanced may be ineffective to prevent the detrimental effects of neurodegeneration on neuronal networks and to offer neurocognitive benefits. Therefore, preclinical models might support the discovery of treatment strategies targeting the main hallmarks of the neurodegenerative cascade underlying the pathogenesis of AD. The development of a valuable and standardized animal model of dementia, with a particular focus on AD, aims to resemble various clinical features of the disease, including its etiology, pathophysiology, and symptomatology, with the advantage that neuronal deficits could be established in a timedependent manner (Jacobsen et al., 2006; van Dam and de Deyn, 2006) . Although metabolic, anatomic, and physiologic differences between humans and other species are relevant key factors when results from animal models should be translated into clinical studies, data in the literature extensively highlight the importance of animal models and behavioral paradigms as valuable tools to unravel the molecular pathways involved in the progression of AD pathology (van Dam and de Deyn, 2006) . Moreover, the availability of experimental paradigms that enable the assessment of appropriate behavioral outcomes for AD studies contributes toward the successful use of these models in evaluating the efficacy of pharmacological treatment and enabling researchers to foster further advances in the drug discovery pipeline.
The present review provides an overview of the most commonly used rodent models developed to study the main neural dysfunctions occurring in the AD brain, with a particular focus on classical neurotransmitter-signaling alterations underlying cognitive dysfunctions. We will also discuss recent findings on novel pharmacological agents -currently under clinical development -acting on specific neurotransmitter receptors and related signaling pathways involved in the pathophysiology of AD.
Evolution of the amyloid cascade hypothesis
Reviewed for the first time by Hardy and Higgins (1992) , the amyloid cascade hypothesis has undoubtedly played a central role in advancing scientific knowledge of the pathogenesis of AD. This hypothesis postulated that the cerebral deposition of Aβ was the core pathological event leading to the formation of extracellular amyloid plaques, which was considered the first hallmark of the AD brain. Aβ is generated through a proteolytic process from the amyloid precursor protein (APP), a type-I transmembrane protein that is highly expressed in neurons (Shoji et al., 1992; Qiu et al., 1995) . Two principal APP processing pathways have been described (Chow et al., 2010) . The amyloidogenic pathway combines sequential cleavages by β-secretase and γ-secretase and leads to the generation of an extracellular soluble form of APP (sAPPβ), C-terminal fragments (CTF 99 and CTF 89) and the release of Aβ peptides of various length ranging from 38 to 43 amino acids. The antiamyloidogenic pathway, which precludes Aβ production, is mediated by the protease activity of α-secretase and γ-secretase and generates a long secreted form of APP (sAPPα), and C-terminal fragments (CTF 83, p3 and APP intracellular domain 50). The β-secretase activity represents the rate-limiting step in the amyloidogenic pathway and is mediated by the β-site amyloid precursor protein cleaving enzyme-1 (BACE-1), whose expression and activity has been shown to be involved in the pathology of AD. Indeed, a reduction in neuronal Aβ formation has been reported in studies using BACE-1 knockout mice (Luo et al., 2001; Roberds et al., 2001) , whereas an upregulation of BACE-1 expression and activity has been detected in the brain of AD patients (Yang et al., 2003) . γ-Secretase is an enzyme complex whose activity depends on the interaction between the following proteins: anterior pharynx defective 1, presenilin enhancer 2, nicastrin, and presenilin (PSEN1 and PSEN2) (Wolfe, 2008) .
The finding of an autosomal dominant inheritance pattern in some early-onset familiar AD has paved new approaches toward the development of transgenic AD animal models and further supported the role of Aβ in AD research. The mutations, which were proposed to be involved in Aβ neurotoxicity underlying cognitive impairments, include genes associated with the amyloid processing machinery, such as APP, PSEN1, and PSEN2 (Goate et al., 1991; Levy-Lahad et al., 1995) . The release of Aβ fragments is increased because of gene mutations, whereas different forms of the peptide are accumulated in the brain because of an imbalance between its overproduction and reduced clearance. Aβ 1-40 is the most abundant but less toxic form found in the cerebrospinal fluid, whereas the Aβ 1-42 form is more hydrophobic, prone to self-aggregation at low concentrations, and its accumulation has been reported in AD brains (Gouras et al., 2000; Querfurth and LaFerla, 2010) .
Although the traditional amyloid hypothesis, linking Aβ deposition to the progression of AD, was supported by scientific evidence, there is no close correlation between insoluble plaque density and cognitive deficits (Arriagada et al., 1992; Dickson et al., 1995; Terry, 1996) . In light of this, it is worth mentioning that the therapeutic approach of either reducing Aβ deposition or increasing its clearance did not yield the expected results. Both γ-secretase inhibitors and monoclonal antibodies targeting fibrillar/ oligomeric Aβ did not reach the market, to become available for AD patients, because of pharmacokinetic limitations or significant toxicities (Mancuso et al., 2011) . The main reasons for these failures were as follows: (i) the low ability of the drug candidate to cross the blood-brain barrier and reach pharmacological concentrations in the brain, as occurred for tarenflurbil; (ii) the appearance of highly toxic adverse effects, such as skin cancer or brain vascular edema, which occurred in AD patients treated with semagacestat or bapineuzumab, respectively; (iii) the lack of a positive correlation between the marked reduction in brain amyloid plaques and a significant improvement in cognitive functions in AD patients treated with these agents (Mancuso et al., 2011) .
Thus, significant research in the last decade has advanced a novel hypothesis that highlights the role of soluble forms of Aβ as the main cause of neurotoxicity (Selkoe and Hardy, 2016) . Different studies have supported this hypothesis, showing that soluble species of the peptide, rather than neuritic plaques, correlate best with disease-related toxicity. In this respect, a strong association has been shown between abnormal cerebral levels of soluble Aβ forms and a loss of synaptic plasticity (Wilcox et al., 2011; Park et al., 2013) , inhibition of longterm potentiation (LTP) (Walsh et al., 2002) , alteration of glutamatergic synapses (Shankar et al., 2007; Green and LaFerla, 2008; Canas et al., 2014) and cognitive impairment (Ferreira and Klein, 2011; ; Morgese et al., 2014; Tucci et al., 2014; Balducci et al., 2017) . Moreover, the neurotoxicity of soluble species of Aβ and their contribution toward the neuropathological cascade of AD has also been shown to be mediated by driving the signaling pathways involved in the phosphorylation of tau protein (Gotz et al., 2010; Ittner et al., 2010; Querfurth and LaFerla, 2010) . Solanezumab is a monoclonal antibody that binds specifically to soluble Aβ, altering the sticky characteristics of the peptide, preventing aggregation and, theoretically, preventing amyloid plaque formation (Anonymous, 2016a) . Prespecified secondary analysis of pooled data from two phase III studies in patients with mild-to-moderate AD (EXPEDITION1 and EXPEDITION2) showed that solanezumab (400 mg intravenously every 4 weeks for 18 months) significantly reduced the cognitive function in patients with mild disease, but not in those with moderate disease (Anonymous, 2016a) . The effect of solanezumab was preserved within a prespecified amount in patients treated in the early stages of mild AD compared with patients who received the drug in a later stage (Anonymous, 2016a) .
Tau is a soluble microtubular protein that promotes stabilization and assembly of axonal microtubules and regulates axonal transport under physiological conditions. Hyperphosphorylation and aggregation of tau, mediated through several protein kinases and phosphatases, leads to the accumulation of toxic species of soluble tau and NFT, which are the second histopathological hallmark of AD. As mentioned above, the function of tau protein is influenced by Aβ as the peptide increases tau aggregation and prevents the degradation of hyperphosphorylated tau. However, it has also been pointed out that Aβ neurotoxicity is linked to the endogenous concentration of tau. Indeed, behavioral deficits induced by Aβ were reverted by reducing tau levels in an AD mouse model (Roberson et al., 2007) . Similar to the Aβ-induced pathology, hyperphosphorylated tau protein levels increase pathology significantly by triggering a widespread neurodegeneration and synaptic deficits that ultimately lead to memory failure and cognitive dysfunctions (Berger et al., 2007; Roberson et al., 2011; Di et al., 2016) . Despite the well-established role of tau protein in the pathogenesis of AD, two first-generation drug candidates developed to target tau protein did not reach the market. Methylthioninium (30 and 60 mg, three times daily per os for 12 months) and intranasal davunetide (5 and 15 mg, twice a day for 12 weeks), both of which inhibit tau protein phosphorylation and dissolve tau aggregates, improved cognitive ability in mild-tomoderate AD patients in phase II clinical trials (Anonymous, 2016b (Anonymous, , 2016c . However, despite these interesting results, methylthioninium and davunetide were withdrawn from clinical development in 2012 and 2015, respectively (Anonymous, 2016b (Anonymous, , 2016c . Currently, second-generation inhibitors of tau protein, with improved bioavailability and tolerability, are under clinical development and TRx 0237 is one of these (Anonymous, 2016d) . TauRx provided positive results from a phase III trial in July 2016 showing that, in a preplanned analysis of a small population subgroup that received TRx 0237 as a monotherapy (75 or 125 mg/day per os), there was a statistically significant benefit on cognitive and functional outcomes, as well as slowing down of brain atrophy (Anonymous, 2016d) .
Various molecular mechanisms of neurodegeneration in AD linking neuronal toxicity to Aβ and tau protein have been hypothesized, such as neuroinflammation, oxidative stress, impaired cell stress response, mitochondrial dysfunction, lipid metabolism, apoptosis, disruption of Ca 2 + homeostasis, reduced cytoskeletal integrity, alterations of Notch signaling, enzymatic deregulation (phosphatases, kinases, proteases), epigenetic changes, and, most importantly, the failure of neurotransmitter pathways (reviewed in Woo et al., 2009; Craig et al., 2011; Liu et al., 2013; Zhao and Zhao, 2013; Barone et al., 2014; Heneka et al., 2015; Sanchez-Mut and Graff, 2015) . However, none of the these mechanisms alone can account for all the histopathological and multifactorial molecular changes described in AD.
Spontaneous rodent models of Alzheimer's disease
Studies on naturally aging rodents did not show the neuropathological changes that resemble the characteristic hallmarks observed in AD patients. Indeed, no signs of amyloid plaque or NFT formation, neuroinflammation, or neurodegeneration were found in aging rodents. Their contribution toward AD research is prompted by the manifestation of cognitive impairments because of normal brain aging and behavioral dysfunctions that correlate with AD-relevant neurobiological alterations occurring during disease progression (Erickson and Barnes, 2003; van Dam and de Deyn, 2006) . Moreover, these models represent a key to unraveling complex molecular mechanisms underlying cognitive deficits observed in senile humans, as well as toward exploring the role of accelerated aging in the pathogenesis of neurodegenerative disorders.
Senescence-accelerated mouse model
The senescence-accelerated mouse (SAM) was the first aging rodent model to be described, and was established through phenotypic selection from a common genetic pool of the mouse AKR/J strains (Takeda et al., 1981) . On the basis of the degree of senescence and age-related pathologic characteristics, the SAM model was classified into two substrains: nine major senescence-accelerated mouse-prone (SAMP) strains that showed earlier onset along with irreversible advancement of aging and three SAM-resistant strains with normal development and aging processes. Particular attention was paid to the SAMP-8 model that shows several neuropathological phenotypes similar to those reported in AD, and is characterized by early development of cognitive deficits in a variety of learning paradigms, along with depressivelike behavior, reduced anxiety-like behavior, and altered circadian rhythm of motor activity and drinking behavior (Miyamoto, 1997; Takeda, 2009; Perez-Caceres et al., 2013) . Table 1 summarizes the results in various behavioral paradigms used to assess learning and memory dysfunctions in the SAMP-8 model. Different biochemical and immunohistochemical studies have been carried out to clarify, from a mechanistic point of view, the observed cognitive deficits. Interestingly, altered processing of APP and increased levels of Aβ have been evidenced in the hippocampus of SAMP-8 mice between 4 and 12 months of age, suggesting a direct implication of the peptide in the pathogenesis of learning and memory impairments (Morley et al., 2000) . Indeed, administration of Aβ antibodies or specific APP antisense oligonucleotides, before training trials, improved the acquisition and retention impairments observed during testing Morley et al., 2002; Poon et al., 2004; Zhang et al., 2011) . Other features reported in the pathogenesis of AD and also shared by SAMP-8 mice include the alteration of PSEN gene expression (Kumar et al., 2009) , hyperphosphorylation of tau (Canudas et al., 2005) , increased oxidative stress (Butterfield and Poon, 2005) , and modulation of signal transduction pathways (Sowell and Butterfield, 2011) . The failure of SAMP-8 mice in learning and recalling new information has been linked to age-related changes in septohippocampal functioning that interferes with neurotransmitter activity. In this respect, it has been hypothesized that the reduction of the serotonergic receptor activity in the septum triggers the upregulation of γ-aminobutyric acid (GABA) neuronal signaling, which, in turn leads to reduced ACh neurotransmission in the hippocampus (Strong et al., 2003) . Moreover, age-related alterations in the expression of muscarinic M1, serotonin (5-HT) 5-HT 1 and 5-HT 2 , GABA B , and NMDA receptors have been reported in the cerebral cortex and hippocampus of SAMP-8 mice (Nomura et al., 1997; Flood et al., 1998) . Pharmacological treatments targeting the aforementioned receptors and signaling pathways improved behavioral and cognitive deficits, supporting the use of the SAMP-8 model as a valuable tool in AD-related research.
Octogon degus
Although the majority of AD cases are sporadic, basic research has mainly focused on the development of rodent models resembling pathological phenotypes of familial AD. However, Octogon degus is a diurnal rodent native to South America, described as a promising candidate model for sporadic neurodegenerative diseases, as it was shown to spontaneously develop the characteristic histopathological hallmarks of AD in aged wild-type strains without any genetic or pharmacological manipulation (Inestrosa et al., 2005) . Over the last few years, studies on aged degu have reported a high degree of genetic homology between the degu and human Aβ peptide, with only a single amino acid difference in peptide sequence. Interestingly, intracellular and extracellular deposits of Aβ, accumulations of et al. (1989) hyperphosphorylated tau protein, and astrogliosis have been shown to develop naturally in the cortical and hippocampal areas of aged O. degus, suggesting a similarity to the progression of AD observed in humans (Inestrosa et al., 2005; Ardiles et al., 2013) . Another important characteristic of O. degus is in the expression of AChE-rich pyramidal neurons in the cerebral cortex of aged animals, shown in a manner similar to those detected in humans (Inestrosa et al., 2005) . A study of whether the pathological features observed in this natural model of AD were correlated with behavioral, molecular, or synaptic changes found an age-dependent memory impairment, as indicated by the reduced number of correct choices and the inability to differentiate the novel object from the familiar one in the spatial T-maze and the novel object recognition (NOR) memory paradigms, respectively. An electrophysiological analysis of hippocampal slices of behaviorally tested animals reported altered synaptic transmission and plasticity along with selective postsynaptic deficits in aged O. degus, relative to young animals, thus explaining the cognitive deficits manifested in this model (Ardiles et al., 2012) . On the basis of this evidence, O. degus has gained importance as a suitable model for a better understanding of the mechanisms underlying the pathogenesis of this insidious human disease and its natural progression (Tarragon et al., 2013) . However, a very recent study by Steffen et al. (2016) has re-evaluated the use of O. degus as a valuable natural model of sporadic AD by examining neuropathological changes in young and aged animals born and bred in captivity (Steffen et al., 2016) . In contrast to previous findings, the authors did not observe Aβ peptide deposition, NFT accumulation, evident signs of age-related neurodegeneration, or significant neuronal loss in their O. degus model, suggesting that a deeper investigation is mandatory to validate this model as suitable for AD research. Particular attention should be paid toward developing this model because either the use of different environmental conditions or experimental and methodological approaches, or non homogeneity within the same wild-type colony, may render difficult the comparison and interpretation of data obtained by various research groups.
Pharmacologically induced models
The strategy to modulate neural transmission by the administration of agents that induce or inhibit neurotransmitter-signaling pathways has been suggested as an approach to trigger behavioral and cognitive impairments related to AD. The main rodent models proposed for this category were developed according to the classical neurotransmitter hypothesis of AD.
The first animal model of AD, developed in the 1980s, was based on the cholinergic hypothesis, which suggested that a progressive impairment of the cholinergic network was the major contributor toward memory deficits observed in patients. Among the rodent models, the scopolamine-induced amnesia model has been used for many years as a rapid screening tool for the characterization of potential drugs aimed to improve memory loss. Animals treated before training with the muscarinic cholinergic antagonist, scopolamine, and tested in a wide variety of memory-related tasks, showed significant cognitive impairments (Ennaceur and Meliani, 1992; Buckton et al., 2001; Buccafusco, 2009) . Despite criticism of the reduced selectivity of scopolamine to inhibit presynaptic versus postsynaptic muscarinic receptors, the versatility and the validity of this model have been supported by studies showing the ability of cholinomimetic drugs to prevent scopolamine-induced memory deficits (Bejar et al., 1999; Takahata et al., 2005; van der Staay and Bouger, 2005; de Bruin and Pouzet, 2006) . However, it has been more difficult to interpret experimental data on the effects of nicotinic receptor antagonists, such as mecamylamine or chlorisondamine, on cognitive functioning in rats (Levin et al., 1990; Decker and Majchrzak, 1993; Moran, 1993) . Although high doses of mecamylamine induced memory impairment, lower doses seemed to improve learning in rats (Levin and Caldwell, 2006) . Interestingly, in a model of scopolamine-induced amnesia, cognitive parameters were improved by the concomitant administration of a low dose of mecamylamine, probably by preventing the excessive activation of nicotinic receptors because of an increase of ACh release induced by scopolamine (Newman and Gold, 2016) .
Another pharmacologically induced model of AD was developed on the basis of the glutamatergic hypothesis. Under physiological conditions, glutamate and NMDA receptors play a fundamental role in learning and memory processes, and dysfunctions of glutamatergic neurotransmission have been reported to be involved in the pathophysiology of AD. The loss of glutamatergic functions, reduction of NMDA receptors, and altered expression of glutamate transporter have been reported in neocortical and hippocampal areas of AD patients (Butterfield and Pocernich, 2003) . Studies carried out to evaluate the effects of NMDA receptor antagonists, such as dizocilpine maleate, D-2-amino-5-phosphonopentanoate, phencyclidine, and 2-amino-4,5-(1,2-cyclohexyl)-7-phosphonoheptanoic acid (NPC 12626), on cognition functions, reported an impairment of both acquisition and recall of previously acquired information in many paradigms that assess cognitive functions (Davis et al., 1992; Fadda et al., 2006; Morris et al., 2013) .
In the past, preclinical and clinical studies were mainly focused on the cholinergic and glutamatergic hypothesis of AD because results from postmortem human brains and animal models did not show any significant loss of the GABAergic neuronal network (Rissman et al., 2007) . GABAergic neurons are the primary inhibitory neurons in the central nervous system that contribute toward preservation of the stability of synaptic signaling through
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interaction with cholinergic and glutamatergic neuronal pathways. Recent reports support the hypothesis that a dysfunction of the GABAergic system, including GABAergic neurons, receptors, and transporters, has a major impact on the excitatory-inhibitory balance of neural circuitries possibly affecting memory and learning behaviors (Nava-Mesa et al., 2014) . The role of GABAergic neurotransmission in cognitive processes has been shown in many pharmacologically induced rodent models. In particular, the administration of tiagabine, a GABA-transporter inhibitor, impaired acquisition and retrieval of spatial memory in the Morris water maze (MWM) (Schmitt and Hiemke, 2002) . Simultaneously, mice treated with muscimol or baclofen (GABA A and GABA B receptor agonists, respectively) at short intervals after training dose dependently decreased memory consolidation of inhibitory avoidance learning (Castellano et al., 1993) . The role of GABAergic neurotransmission with respect to AD-related synaptic dysfunction has been studied recently in genetically modified models of AD that also show the neuropathological features of this disease. Indeed, the pharmacologically induced models are valuable to increase our knowledge of the neural mechanism underlying learning and memory deficits.
Similarly, chemically induced models provided by intracerebral injections of neurotoxic agents, such as the cholinotoxins ethylcholine aziridinium ion (AF64) and saporin, ibotenic acid, domoic acid, and kainic acid, are suitable for investigation of singular signaling pathways involved in the etiology of cognitive disorders (for a review, see Anand et al., 2012) . Nevertheless, these models are limited in studying only a specific signaling pattern, in terms of cholinergic, glutamatergic, or GABAergic neurotransmission, in the absence of histopathological hallmarks of AD and do not provide a correlation between disease progression and the downstream neuronal alterations triggered by Aβ or tau protein.
Nontransgenic models Soluble β-amyloid infusion models
By the 1990s, with the introduction of the amyloid hypothesis, researchers began focusing on attempts to generate animal models that resemble the main histopathological, neurochemical, and behavioral alterations observed in AD patients. According to the hypothesis that amyloidogenesis and plaque formation are the primary hallmarks of AD pathogenesis, Frautschy et al. (1992) developed the first rodent AD model by injecting mature amyloid plaques extracted from human AD brains into the cortex and hippocampus of rats. Histochemical analysis confirmed the presence and persistence of Aβ vascular deposits and senile plaques in the rat brain (Frautschy et al., 1992) . However, this first model, along with the evolution of the amyloid cascade hypothesis, paved the way for other innovative lines of research focusing on the pivotal role of soluble Aβ species in the development of AD-like phenotypes reminiscent of humans. The aim was to reproduce several pathological aspects of the disease by injecting exogenous soluble forms of Aβ peptide (from monomers to oligomers of different molecular weights) directly into the rodent brain by intracerebroventricular or intracerebral infusion.
The advantage of intracerebroventricular administration is the rapid delivery of the peptide throughout the brain without damaging the injection site, which could trigger inflammation or brain area injuries that, in turn, might be responsible for synaptic plasticity impairment and memory dysfunctions. The literature includes both acute models established by a single injection, and chronic models developed by either repetitive or continuous delivery of the peptide. Although the gradual increase in brain Aβ levels by the use of osmotic and micro-infusion pumps or microdialysis seems to better fit with human disease progression, the cognitive deficits induced by Aβ are not directly correlated with the time interval of Aβ exposure (Puzzo et al., 2015) .
Among the various soluble forms of Aβ peptide, the Aβ 25-35 , Aβ 1-40, and Aβ 1-42 sequences have been the most commonly used to design rodent Aβ infusion models. In particular, Yamada et al. (2005) developed a mouse AD model on the basis of repeated infusion of Aβ 25-35 , a neurotoxic nonamyloidogenic peptide fragment, delivered through an implanted cannula system into the cerebral ventricle. Results from this study showed a dosedependent memory loss in the Y-maze test along with a significant reduction of choline acetyltransferase (ChAT) immunoreactive neurons in the medial septum, suggesting that peptide neurotoxicity was mediated through the cholinergic system dysfunction in the hippocampus (Yamada et al., 2005) . A number of studies have shown that a single intracerebroventricular injection of Aβ 25-35 also induced learning and memory impairments, hippocampal morphological changes, and time-course dysregulation of the ACh system (Stepanichev et al., 2006; Alkam et al., 2008; Zussy et al., 2011) . A reduction of muscarinic receptors and inhibition of nicotine-evoked ACh release in the cerebral cortex has been reported in rats 2 weeks after Aβ 25-35 infusion. These Aβ 25-35 -induced alterations in cholinergic neurotransmission have been hypothesized to be the main mechanisms that mediate the effects of the peptide on LTP. Indeed, the dose-dependent impairment of LTP induction, detected in the dorsal hippocampus of animals injected with Aβ 25-35, was prevented by the coadministration of an AChE-I, named huperzine A (Chambon et al., 2011) . Long-term effects of the peptide have been evaluated 6 weeks and 6 months after intracerebroventricular Aβ 25-35 injection, and the results were comparable to the amyloid-induced behavioral and synaptic effects described above (Stepanichev et al., 2003; Zussy et al., 2013) .
Behavioral data obtained after an acute intracerebroventricular injection of Aβ 1-40 to mice also showed a significant cognitive decline, which was supported by a biochemical analysis showing a reduction in synaptophysin levels, an increase in AChE expression in the hippocampus, and a decrease in hippocampal and cortical ChAT activity (Medeiros et al., 2010; Santos et al., 2012) .
In-vivo and in-vitro studies have evaluated the effects of Aβ 1-40 injection on LTP. The results suggested that inhibition of LTP, as observed following Aβ 1-40 administration, might be the main cause of cognitive impairments reported in AD patients with increased Aβ 1-40 brain levels, and could be directly correlated with synaptic deficits induced by the peptide (reviewed in Chambon et al., 2011) . The relationship between peptide and memory processing has also been established by experimental evidence showing that a continuous intracerebroventricular injection, multiple, or single intrahippocampal injections of Aβ 1-40 immediately before training induced working and reference memory deficits (Nitta et al., 1994; Malin et al., 2001) . Interestingly, when Aβ 1-40 was injected in rat hippocampus immediately before testing in the eight-arm radial maze, animals showed impaired retention only on the day of testing without any effect on working memory on the following days, suggesting a rapid and transient effect of Aβ 1-40 on memory consolidation without affecting the ability to remember a previously well-learned task (Sweeney et al., 1997) .
It is very well documented that the most commonly used nontransgenic rodent model in the field of AD research was obtained by the administration of soluble Aβ 1-42 species, which are considered the most amyloidogenic form of the peptide. Numerous studies have assessed the behavioral and neuronal effects after an acute intracerebroventricular injection or a continuous infusion of Aβ 1-42 . Studies using a variety of experimental paradigms reported a marked Aβ 1-42 -induced impairment of learning and memory in both spatial and nonspatial conditions, irrespective of the dose, schedule, or administration timing (Chambon et al., 2011) . Less consistent data have emerged from studies where animals received an intrahippocampal administration of Aβ 1-42 ; in contrast to repeated injections that caused deficits in hippocampusdependent memory using the passive avoidance and Y-maze tasks, a single treatment failed to affect cognitive parameters (Brouillette et al., 2012; Ghasemi et al., 2014) . Conversely, a recent study has addressed the detrimental effect of Aβ 1-42, injected directly into the dorsal hippocampus, on working but not spatial memory in mice tested 7 days after treatment (Faucher et al., 2016) .
The difficulty of merging and integrating different scientific findings on the cognitive effects induced by intracerebral administration of the Aβ 1-42 peptide is related in part to the different technical approaches of peptide preparation, site of injection, and the distinct nature of the so-called 'soluble' peptide candidates. As Aβ function is highly correlated with its conformation, defining the peptide structure and morphology is critically important. In our laboratory, we use a validated rat model receiving an intracerebroventricular injection of Aβ 1-42 solution containing mainly soluble monomers, as characterized and described by atomic force and transmission electronic microscopy (Morgese et al., 2015) . Results from our studies showed that an acute intracerebroventricular injection of soluble Aβ 1-42, 2 h or 7 days before testing in the NOR paradigm did not affect short-term memory (Colaianna et al., 2010; Tucci et al., 2014) . However, Aβ 1-42 acutely interfered with memory consolidation, as shown by the inability of animals to discriminate the novel object from the familiar one in a long-term memory test or to retrieve a learned behavior in the passive avoidance task Tucci et al., 2014) . Interestingly, the Aβ 1-42 -induced memory impairment was ameliorated by memantine, an NMDA receptor antagonist, administered immediately after the training phase, suggesting a potential role of the glutamatergic system in the pathogenesis of early cognitive deficits induced by Aβ .
Other cellular mechanisms proposed to explain peptide neurotoxicity include reduced levels of the NMDA receptor subunit NR2B, a marked neuronal loss in the hippocampus of treated animals, in-vivo LTP inhibition, and a transient, but not marked impairment of cholinergic system (reviewed in Chambon et al., 2011) . A limitation of soluble Aβ infusion models is the fact that these models do not replicate either the Aβ concentrations or the time course of neurodegenerative processes reported in the brain of AD patients. However, they undoubtedly offer a rapid experimental approach and enable researchers to investigate the role of specific sequences or conformations of the peptide on AD-related phenomena. Furthermore, acute models have the advantage of a more accurate understanding of the neural mechanisms underpinning behavioral dysfunctions and synaptic plasticity and provide an appropriate experimental model for the selection of new therapeutic strategies targeting Aβ peptides.
Transgenic models Single transgenic animals
Research progress showing genetic factors as contributors toward the neuropathology of AD has led to important insights into the evaluation of pathogenic mechanisms involved in the progression of AD through the development of an innovative experimental approach: the use of genetically modified animals. Among the high number of these in-vivo models, rodents seem to be more attractive because of their well-characterized genome that facilitates genetic targeting and manipulation, as well as their short lifespan, easy breeding, and economic advantage. The main methods for generating transgenic rodent models consist of injecting the transgene construct (gene of interest, enhancer and promoter) into a one cell embryo at the pronuclear stage or through gene targeting technology that first engineers the recombination of a DNA fragment with embryonic stem cells, followed by injection into rodent blastocysts (Elder et al., 2010 ). An excellent review, published recently by Combs et al. (2016) , has focused on the recent advances in viral vector technology, particularly using recombinant adenoassociated viruses, as a novel and effective tool for modeling neurodegenerative diseases. The aim of these approaches was to develop a model that fully replicates one or both the neuropathological hallmarks of AD.
The first transgenic mice models introduced in the mid1990s were classified as models of amyloid pathology because they were characterized by plaque formation and were developed by mutations in the APP gene, which is not only the precursor molecule whose cleavage generates Aβ but is also the target of familial AD mutations. The PDAPP mouse was the first model generated, which expressed a human APP minigene carrying the Indiana (V717F) mutation under the platelet-derived growth factor promoter. This model presented plaque pathology in the neocortex and hippocampus starting at 3 or 6 months of age, respectively. Although no signs of neuronal loss were detected, high levels of Aβ 1-42, hippocampal atrophy, and a reduction in basal synaptic transmission were reported (German et al., 2005) . From a behavioral point of view, slight deficits in MWM and NOR have been found in 6-month-old mice, suggesting a linear correlation with plaque deposition in the hippocampus, the brain area significantly involved in memory formation in these two behavioral paradigms (Chen et al., 2000) .
Other single transgenic APP models are the Tg2576 and APP23 models, which express the Swedish double mutation (human APP isoforms containing K670N/ M671L or KM670/671NL mutations) under the control of hamster prion protein or murine thymocyte differentiation antigen-1 (Thy-1) promoters, respectively. Both models show increased levels of Aβ 1-40 and Aβ 1-42 , leading to extensive amyloid plaque deposition. Contrasting results were found in a memory-related behavioral test, but, interestingly, the amyloid pathology reported was not associated with cognitive impairments, thus suggesting other molecular mechanisms of neurodegeneration involved in learning and memory processes (Platt et al., 2013) . Intriguingly, in the cortex and hippocampus of Tg2576 mice, reduced binding levels of both M1 and M2 ACh receptors, together with receptor-G-protein coupling, were detected as early as 7-8 months of age (Apelt et al., 2002) . The activation of muscarinic ACh receptors by carbachol increased the frequency and amplitude of spontaneous GABA-induced inhibitory postsynaptic currents in frontal cortex pyramidal neurons, and this effect was mediated by protein kinase C (Zhong et al., 2003) . Moreover, Lalande et al. (2014) reported metabolic changes in glutamate metabolism in a Tg2576 transgenic line and showed a significant reduction in hippocampal and rhinal cortical glutamate levels as early as 1 month, reaching the peak at 11 months of age (Lalande et al., 2014) . Finally, in the hippocampus of Tg2576 transgenic mice, a significant reduction in both 5-HT transporter (SERT) and 5-HT 1B receptors was found, together with an increased 5-HT turnover (Tajeddinn et al., 2015) .
Multiple transgenic animals
The TgCRND8 transgenic line benefits from combining both the Swedish (KM670/671/NL) and the Indiana (V717F) mutations within the human APP695, the isoform most commonly expressed in neurons. The rapid onset of plaque development from the age of 3 months and of marked neuritic pathology at 5 months were responsible for the premature mortality of this mouse model (Chishti et al., 2001) . Although no significant alterations in locomotor activity, exploratory activity, or neuromuscular function were observed in TgCRND8 mice compared with the wild-type line, early deficits in memory acquisition and recall of the MWM were hypothesized to depend on impairment of hippocampal synaptic function because of changes in the NMDA/α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) current ratio (Chishti et al., 2001; Tozzi et al., 2015) . Furthermore, in the TgCRND8 mouse model of AD, a significant reduction in hippocampal neurons positive for glutamate decarboxylase 67, the key enzyme in GABA synthesis, was detected in 6-month-old animals. The neuronal populations expressing the lowest levels of glutamate decarboxylase 67 are those in the CA1-CA3 fields and in the polymorphic layer of the dentate gyrus (Krantic et al., 2012) . Thus, the genotype-related changes in the fine-tuning of the hippocampal network seemed to be linked to altered synaptic excitability, secondary to reduced GABAergic and increased glutamatergic neurotransmission (Jolas et al., 2002) . A strong age-dependent reduction in noradrenaline (NA) was also detected in the hipppocampus, frontal cortices, and cerebellum of TgCRND8 mice (Francis et al., 2012) .
With the discovery of familial AD mutations in PSEN1 and PSEN2 genes, research focused on the PSEN transgenic rodent models and the combined lines carrying both APP and PSEN1 mutations. Although single mutations in the PSEN1 gene, such as M146L, PS1deltaE9 (exon 9 deleted), and A246E, produced increased levels of Aβ 1-42 without plaque formation, the double transgenic model resulted in a more severe amyloid plaque pathology. In light of this, in the 18-month-old APP-PSEN1 model [generated by crossing a Tg2576 with a PSEN1(M146L) mutation line], fibrillary Aβ deposition was responsible for the appearance of dystrophic neurites and the degree of dystrophy was related to Aβ plaque size (Holcomb et al., 1998) . The earliest memory deficits in this model were reported in associative learning and appeared at 4-5 months of age, whereas an impairment in working memory occurred very late and became consistent by 15 months of age (Webster et al., 2014) . It is not clear why the single transgenic PSEN line did not present plaque formation, but it could probably be related to the reduced Aβ 1-42 concentrations released in this mouse model compared with the APP or double APP-PSEN transgenic models. Another well-studied model based on the bigenic APP/ PSEN approach is the APP/PSEN1DeltaE9 mouse, which expresses the Swedish APP mutation and a mutant human PSEN1 gene carrying the deletion of exon 9 (deltaE9) driven by the mouse prion promoter. High levels of Aβ 1-42 and amyloid plaque deposits were detected starting at 6 months of age, but no effect on cognitive parameters was observed. However, Aβ deposition became more abundant in hippocampal and cortical areas of 18-month-old cohorts, and a statistically significant correlation was found between amyloid load, cognitive impairments, and cholinergic markers' expression at this time point (Savonenko et al., 2005) . A severe reduction in ChAT activity or increase in AChE was also detected in the cortex and hippocampus of middle-aged APP/PSEN1DeltaE9 mice, thus confirming that the derangement in ACh-synthesizing machinery occurs in early stages of the disease and progresses (Perez et al., 2007; Machova et al., 2008) . β-Amyloid deposition decreased the density of vesicular ACh transporter in the hippocampus of the APP/PSEN1DeltaE9 transgenic mouse, thus impairing ACh release in the synaptic cleft. It is also worth mentioning the evidence of a progressive decline of both muscarinic M1 and M2 receptors in the cortex and hippocampus of APP/PSEN1DeltaE9 mice (Machova et al., 2008) . Other neurotransmitter systems have been reported to be correlated with amyloid pathology in this transgenic model that might have important implications for the preclinical diagnosis of AD. In particular, an age-dependent decrease in labeling of glutamate-C4 and glutamine-C2, together with a decrease in the vesicular glutamate transporter 1 (VGLUT1) and a compromised hippocampal LTP (because of a decreased AMPA receptor number and AMPA receptor-mediated synaptic transmission), resulted in a gradual impairment in spatial memory in APP/ PSEN1DeltaE9 mice between 6 and 15 months of age (Tiwari and Patel, 2012) . The same transgenic animals showed an increased number of glutamatergic dystrophic neurites with a lower presynaptic bouton density (Bell et al., 2003) . In addition, nuclear magnetic resonance spectroscopy showed a significant decrease in labeling of GABA-C2, confirming a reduction in GABA levels. Moreover, in the same experimental model, the administration of picrotoxin, a GABA A receptor antagonist, reversed memory impairment in adult animals (Yoshiike et al., 2008) . Intriguingly, a recent study by Jo et al. (2014) documented how, in the APPswe/PSEN1DeltaE9 transgenic mouse, GABA is aberrantly produced and released from astrocytes, and, by acting on presynaptic GABA receptors, reduces synaptic plasticity in the dentate gyrus of these animals. However, GABAergic transmission could undergo modifications secondary to the activation of different neurotransmitters. Ultimately, a reduction in 5-HT occurred earlier in the amygdala and was less severe than in the hippocampus of APPswe/ PSEN1DeltaE9 transgenic mice (Lin et al., 2015) . Importantly, the 5-HT 4 receptor agonist SSP-002392 decreased soluble and insoluble Aβ in the hippocampus (Tesseur et al., 2013) and chronic treatment with the selective serotonin-reuptake inhibitor citalopram caused a 50% reduction in brain plaque load (Cirrito et al., 2011) .
A major limitation of the transgenic strains in terms of the amyloid pathology is the lack of NFT development, which was partly overcome by the introduction of transgenic models of tau pathology or by crossing human mutated tau and APP lines. Although these models manifested plaque deposition along with tau phosphorylation, NFT formation, and neuronal impairment, their development did not reproduce the characteristic temporal and spatial features observed in human AD brains. Thus, Oddo et al. (2003) generated a triple-transgenic AD model (3xTg-AD) to further elucidate the mechanistic features involved in the amyloid cascade hypothesis, which posits the neurotoxic role of Aβ in tau pathology. Single-cell embryos from homozygous PSEN1 (M146V) mutant mice were injected with two human transgenes (APP K670N/M671L Swedish mutation and P301L tau mutation) and expressed under the control of a Thy-1.2 neuronal-specific promoter. The advantage of harboring three mutant genes in the same animal model was observed during the characterization of the pathological findings: 3xTg-AD mice progressively developed amyloid and tau pathology, with a gradual and regionalspecific profile reminiscent of the progression observed in the human AD brain (Oddo et al., 2003) . Until 4-6 months of age, intraneuronal Aβ is present in its monomeric form, whereas plaque pathology initiates at 6 months of age affecting first the frontal cortex, and then spreading throughout the hippocampus with aging. The progression of tau pathology occurs after amyloid deposition and is first detected in pyramidal neurons at ∼ 12 months and advances to affect the cortex (Oddo et al., 2007) .
In a further effort to determine a relationship between amyloid/tau pathology progression and cognitive dysfunctions, many behavioral studies have investigated the time course of pathological events reported in previous studies. Although no performance alterations were shown at 2 months of age, cognitive impairments manifested as long-term retrieval deficits during acquisition training in the MWM were reported in 4-month-old 3xTg-AD mice, suggesting the involvement of soluble Aβ species in the onset of cognitive deficits in the early stages of AD pathology (Billings et al., 2005) . Interestingly, marked memory deficits in both MWM and NOR tasks were found in aged 3xTg-AD mice, consistent with the timecourse of development of the amyloid and tau pathology in brain areas (Billings et al., 2005; Arsenault et al., 2011) . Moreover, a study carried out in 9-month-old mice showed performance impairments in a touchscreen-based 5-choice serial reaction time test because of a deficit of attention over the task duration mediated probably by the cholinergic system to the frontal cortex as behavioral deficits were reverted by the AChE-I donepezil (Romberg et al., 2011) . In this respect, a severe reduction in ChAT activity or increase in AChE was detected in the cortex and hippocampus of 3xTg-AD mice (Perez et al., 2011) . Similarly, studies carried out in a 6-month-old 3xTg-AD model showed a significant reduction in the α7 nicotinic ACh receptor, particularly in the hippocampus (Oddo and LaFerla, 2006) . In the same transgenic model, stimulation of the α7 nicotinic ACh receptor with the selective agonist A-582941 restored cognitive function in aged animals to the same level as age-matched nontransgenic mice (Medeiros et al., 2014) . Additional studies have attempted to investigate a link between the behavioral phenotype of the 3xTg-AD model and specific synaptic or electrophysiological deficits. Indeed, significant damage to the glutamate system was also found in aged 3xTg-AD mice, in which VGLUT1 was reduced in both the hippocampus and the frontal cortex, together with an impairment in mitochondrial bioenergetics in these brain areas (Cassano et al., 2012) .
However, conflicting results were obtained in the 3xTg-AD model, which showed a significant increase in SERT in the hippocampal CA1 stratum molecular at both 3 and 18 months of age (Noristani et al., 2010 (Noristani et al., , 2011 . To better understand the role of the serotonergic system in the pathogenesis of AD, it is necessary to point out how 5-HT-signaling may affect Aβ production. 3xTg-AD mouse fed with a high tryptophan-rich diet showed reduced intraneuronal Aβ density in CA1 compared with animals fed a normal diet. Furthermore, paroxetine, an selective serotonin-reuptake inhibitor drug that increases 5-HT brain levels by blocking the synaptic reuptake, reduced hippocampal Aβ immunoreactive neurons and improved cognitive functions in these animals (Nelson et al., 2007; Noristani et al., 2012) . Importantly, in the 18-month-old 3xTg-AD mice, increased Aβ plaque deposition was paralleled by a significant decrease in NA and dopamine (DA) levels in both the frontal cortex and the ventral hypothalamus. Neurochemical alterations were accompanied by a depression-like behavior, whereas motor function and anxiety-related emotional responses were unaltered (Romano et al., 2014) . In the same animal model, an Aβ-induced decrease in cortical DA transformed LTP into long-term depression, leading to impaired recognition memory (Moreno-Castilla et al., 2016) . Vandal et al. (2016) found a lower basal body temperature and an increased vulnerability to a cold environment that was responsible for synaptic protein loss in the cortex of 3xTg-AD mice as early as 12 months of age. Intriguingly, in these animals, the increase in body temperature was associated with memory improvement (Vandal et al., 2016) .
The development of transgenic rodent models, and, in particular, of the 3xTg-AD model, has not only shown that animal models can show the basic pathological hallmarks of AD, but has also lent more credence to the link between amyloid and tau pathology and to the key role of tau protein in the pathology of AD. Although the 3xTg-AD model does not include all the features of human AD, which takes decades to develop, it is actually one of the most valuable animal models in basic AD research.
Current advances in the pharmacotherapy Alzheimer's disease by targeting the classical neurotransmitters Acetylcholine
In the progression of AD, the release of classical neurotransmitters is impaired significantly in several brain areas. Acetylcholine synthesis and release from cholinergic synaptic terminals is markedly reduced in the hippocampus, amygdala, prefrontal, and temporal cortices of AD patients and this is because of the progressive destruction of cholinergic neurons in these brain areas (Coyle et al., 1983) . However, cholinergic dysfunction and memory impairment occur even earlier than neuronal death and depend on multiple changes occurring in the ACh-synthesizing/releasing machinery. The enormous evidence of the role of brain cholinergic system impairment in the pathogenesis of AD led pharmaceutical companies to develop drugs able to cross the blood-brain barrier and increase brain ACh levels. Currently available on the market are the AChE-Is donepezil, galantamine, and rivastigmine (Mancuso et al., 2011) . By blocking the catabolism of ACh, these three drugs increase the availability and retention of this neurotransmitter in the cholinergic synapse and improve cognitive functions (Mancuso et al., 2011) . However, considering the progressive destruction of cholinergic neurons, mainly in the cortex and hippocampus, the clinical efficacy of AChE-I is restricted to a short time frame and only in those patients in whom cholinergic neurons are still available (Mancuso et al., 2011) . This implies that AChE-I improves memory and cognitive performance only in patients with mild-to-moderate AD, whereas these drugs become ineffective in patients with moderate-to-severe disease (Mancuso et al., 2011) . Interestingly, galantamine was shown to serve as a positive allosteric modulator of the α7 nicotinic ACh receptor, thus amplifying the effects of ACh on both the presynaptic and the postsynaptic neurons (Lopes et al., 2007) . In particular, the allosteric modulation of presynaptic nicotinic ACh receptors allows galantamine to increase presynaptic ACh release. This composite mechanism of action, namely, the inhibition of AChE together with the positive allosteric modulation of the α7 nicotinic ACh receptor, could explain the longer clinical efficacy of galantamine than the congeners donepezil or rivastigmine (Maelicke, 2000) . Worth mentioning among the most promising agents acting on the ACh system and still under clinical development are the following: (a) TAK 071, an orally administered muscarinic M1 ACh receptor-positive allosteric modulator (Anonymous, 2016e) . In May 2016, Takeda initiated a phase I clinical trial to assess the pharmacokinetics, tolerability, and safety of TAK 071 in healthy volunteers or patients with mild AD (Anonymous, 2016e) . Furthermore, Takeda is planning to initiate a phase Ib clinical trial to evaluate the effects of a single dose of TAK 071 on scopolamine-induced cognitive deficit in healthy volunteers (Anonymous, 2016e) ; (b) CPC 201, an oral-active combination of donepezil plus the cholinergic antagonist solifenacin (Anonymous, 2016f) . The rationale for such a formulation, currently in phase II for mild-to-moderate AD patients, is that solifenacin would improve the tolerability of donepezil by reducing major dose-limiting side effects of the latter, allowing significant increases in dosing and potentially resulting in considerably improved efficacy (Anonymous, 2016f) ; (c) MK 7622, a muscarinic M1 AChR-positive allosteric modulator (Anonymous, 2016g) . Merck planned to conduct a phase IIa/IIb clinical trial to assess the efficacy and tolerability of MK 7622 capsules (5-15-45 mg once daily) as an adjunct to donepezil in patients with mild-to-moderate AD. This clinical study ended in April 2016, but the results are not yet available (Anonymous, 2016g) ; (d) encenicline (formerly EVP 6124), an orally administered selective α7 nicotinic ACh receptor agonist, which, in preclinical studies, has shown an increase in ACh and stabilizes glutamate efflux in rat cortex and nucleus accumbens (Huang et al., 2014) . In addition, encenicline increases neuronal synchronization and enhanced synaptic plasticity (Anonymous, 2016h) . Results from a phase IIb trial showed that encenicline (2.0 mg/day for 23 weeks) significantly improved cognition and clinical functions in patients with mild-to-moderate AD (Anonymous, 2016h) . Currently, a phase III safety/efficacy clinical trial in patients with mildto-moderate AD has ended, but the results are not yet available (Anonymous, 2016h) .
Glutamate
The glutamatergic system plays a key role in the pathogenesis of AD. As a consequence of multiple changes occurring in both VGLUT1 and VGLUT2, which are involved in maintaining the glutamate level in synaptic vesicles, and glutamine synthetase, decreased levels of which prevent glutamate reuptake in AD presynaptic neurons, glutamate concentration in the synaptic cleft increases, thus triggering excitotoxic cell death mainly through the activation of the ionotropic NMDA receptors (Revett et al., 2013) . For this reason, the NMDA receptor antagonist, memantine, is currently on the market with the indication to counteract cognitive impairment in individuals with severe AD (Mancuso et al., 2011) . In light of this, it is also important to underline that glutamate is an excitatory neurotransmitter involved in LTP, synaptic plasticity, learning, and memory, and these cognitive effects are mediated mainly by the ionotropic AMPA receptor. Derangement in the glutamate system can be responsible for cognitive impairment by acting at different levels (Keifer and Zheng, 2010; Chang et al., 2012) . Despite the many lines of evidence available in the literature supporting the importance of changes in the glutamatergic system occurring in the AD brain, and their impact on learning and memory, only a few drugs are currently on the market with this indication. Aniracetam, a nootropic drug that enhances glutamate-induced currents and reduces glutamate-receptor desensitization in rat hippocampus (Isaacson and Nicoll, 1991) , exerts pleiotropic neuroprotective effects through the modulation of multiple intracellular pathways. Aniracetam increased cerebral metabolism and promoted ACh release in rat hippocampus. Moreover, at the dosage of 100-300 mg/kg per os, aniracetam significantly counteracted the scopolamine-induced reduction in hippocampal ACh content (Anonymous, 2016i) . In 109 elderly patients with probable AD and in 115 patients fulfilling the criteria for probable AD with mild-to-moderate impairment, aniracetam (1500 mg/day per os) significantly ameliorated cognitive performance by 20-30% with respect to placebo and by 10-20% versus the comparator piracetam (Anonymous, 2016i) . The effects of aniracetam were evident after 60 days of treatment and marked after 60 months (Anonymous, 2016i) . Currently, Servier is developing S47445, an AMPA receptor agonist that increases both the magnitude and the duration of the synaptic response to any given amount of glutamate and activates the expression of protective genes, such as brain-derived neurotrophic factor in neurons (Anonymous, 2016j) . In February 2015, Servier initiated a phase II clinical trial to assess the efficacy and safety of S47445 in patients with mild-to-moderate AD with depressive symptoms (Anonymous, 2016j) . A possible explanation for such a low number of glutamatergic agents under clinical development is that the potential beneficial effects deriving from the potentiation of glutamate release, with the aim of enhancing LTP and synaptic plasticity, are counteracted by the possible toxic effects because of its uncontrolled activation of both ionotropic or metabotropic glutamate receptors and the consequent neuronal death.
γ-Aminobutyric acid
Different from most neurotransmitters, GABAergic transmission seemed to be quite spared in the AD brain, supporting the theory that inhibitory mechanisms are not involved in the pathogenesis of this disease (Rissman and Mobley, 2011) . However, results from transgenic animals only partially confirmed this view and suggested the hypothesis that the GABAergic system undergoes modifications in the AD brain. An indirect way through which GABAergic transmission may contribute toward the development of AD is the presynaptic regulation of noradrenergic and dopaminergic neurons (Werner and Covenas, 2016) . In the brainstem, GABA, by binding to the GABA B receptor, inhibits α 1 noradrenergic inputs arising from neurons located in the locus coeruleus (LC) (Nowak et al., 2006; Werner and Covenas, 2016) . Similarly, through GABA A receptors, GABA inhibits D 2 dopaminergic neuron firing in the hippocampus, contributing toward a decrease in dopaminergic neurotransmission in depressive states Covenas, 2013, 2016) .
Pharnext, Biosystem International, the University of Bordeaux, Segalen, and Inserm are collaborating to develop PXT 864, a combination of baclofen, a GABA B receptor agonist, and acamprosate, a GABA analog, for the treatment of AD (Anonymous, 2016k) . In February 2013, Pharnext initiated the phase IIa PLEODIAL I trial designed to evaluate both the safety and the efficacy of PXT 864 in patients with mild AD; the study enrolled 47 patients in France and was completed in June 2015 (Anonymous, 2016k) . In July 2016, the company reported that PXT 864 could restore the balance between glutamate and GABA signaling, disrupted by Aβ, which appears to be coupled with a global cognitive improvement in a 4-week treatment period (Anonymous, 2016k ). An extension study, PLEODIAL-II, was initiated in June 2013 to evaluate the efficacy and safety of PXT 864 over an extended 24-week period (Anonymous, 2016k) .
Serotonin 5-HT is involved in the regulation of many neural functions, including the sleep-wake cycle, affective control, sexual behavior, locomotion, and motor control (for an extensive review of this topic, see Simic et al., 2016) . These physiological functions are mediated through the binding of 5-HT to seven receptor families, each of which is further divided into subfamilies (Simic et al., 2016) . Consistent with the topic of this paper, two 5-HT receptor families need some further description, namely, 5-HT 4 and 5-HT 6 : both these receptors are postsynaptic and activate adenylyl cyclase through the Gα s protein (Simic et al., 2016) . Extensive downregulation of the serotonergic system has been reported in AD.
Several agents acting on the serotonergic system are under clinical development: (a) PRX-03140 is an orally administered partial agonist at the 5-HT 4 receptor that is under investigation for the treatment of mild cognitive impairment in AD (Anonymous, 2016l) . Although the compound was identified by EPIX, it is currently developed by Nanotherapeutics (Anonymous, 2016l) . As a partial agonist at the 5-HT 4 receptor, PRX-03140 may potentially stimulate the release of ACh in the brain and produce symptomatic improvement. Interestingly, it may also stimulate the α-secretase pathway to cleave APP, preventing its cleavage by β-secretase or γ-secretase, and, ultimately, reducing the formulation of insoluble Aβ plaques and delaying disease progression (Anonymous, 2016l; Johnson et al., 2012) . Moreover, PRX-03140 has been found to increase levels of brain-derived neurotrophic factor (Anonymous, 2016l) . In a phase IIa clinical trial in 80 patients with AD, PRX-03140 (150 mg once daily for 2 weeks) led to a significant improvement in cognitive function, as measured using the ADAS-cog test (Anonymous, 2016l) . Nanotherapeutics was planning to initiate a new phase II clinical trial in AD patients with mild cognitive impairment in late 2015, with completion set for 2016, but as yet, no results have been released (Anonymous, 2016l) . (b) SUVN 502 is an oral formulation of a selective 5-HT 6 receptor antagonist developed by Suven Life Sciences for the symptomatic treatment of AD (Anonymous, 2016m) . The blockade of 5-HT 6 receptors in the brain has been shown to increase glutamate levels and release ACh (Marcos et al., 2006) . Suven Life Sciences initiated a phase IIa clinical trial in September 2015 to evaluate the safety and efficacy of SUVN 502 in patients with moderate AD, who were treated with donepezil and memantine (Anonymous, 2016m) . The study is expected to enroll ∼ 537 patients, who will receive 50-100 mg daily SUVN 502 or placebo (Anonymous, 2016m) . (c) Idalopirdine is an orally active, selective 5-HT 6 receptor antagonist that is being developed by Lundbeck for the treatment of AD (Anonymous, 2016n) . Idalopirdine could modulate the balance between excitation (glutamate) and inhibition (GABA) in the brain through the modulation of 5-HT 6 receptors on glutamatergic neurons and GABAergic interneurons (de Bruin and Kruse, 2015) . Furthermore, idalopirdine enhanced donepezil-induced ACh hippocampal levels in the rat (Herrik et al., 2016) . In the phase II clinical trial LADDER, idalopirdine (30 mg thrice daily) improved cognitive function in donepezil-treated patients with moderate AD (Wilkinson et al., 2014) . Currently, idalopirdine is in phase III development for the treatment of AD in multiple countries including the US and European Union (Anonymous, 2016n) . Several other 5-HT 6 receptor antagonists, such as PF 5212377, AVN 322, and AVN 101, are in phase II development, with promising results.
Monoamines (noradrenaline and dopamine)
The LC and the ventral tegmental area and substantia nigra are involved in the monoaminergic control of brain function as they contain the cell bodies of most noradrenergic and dopaminergic neurons, respectively (Simic et al., 2016) . Noradrenergic neurons project to several brain areas including the cortex, hippocampus, amygdala, and hypothalamus, whereas dopaminergic neurons send their axons to the basal ganglia, nucleus accumbens, hypothalamus, hippocampus, neocortex, and pituitary gland (Oades and Halliday, 1987) . The neurotransmitter NA, by binding to both α and β receptors, contributes toward the regulation of important physiological functions, such as learning, attention, responsiveness to novel stimuli, mood, and the sleep-wake cycle (Simic et al., 2016) . The neurotransmitter DA binds to five receptor families, named D 1 -D 5 , among which the D 2 receptor plays a key role in the modulation of motor control, addictive behavior, and attachment disorder, whereas D 1 and D 3 are involved in psychosis and aggressive behavior (Simic et al., 2016) . In patients with AD, a significant loss of LC noradrenergic neurons occurs and is responsible for symptoms including cognitive impairment and dysregulation of visceral functions, whereas pathological changes in the dopaminergic projections to the hypothalamic tuberomammillary nucleus play a role in causing sleep disturbances and thermoregulation in these patients (Simic et al., 2016) . Currently, Orion is developing an oral α 2c adrenergic receptor antagonist, ORM 12741, for the treatment of AD (Anonymous, 2016o) . A phase II clinical trial assessed the safety and efficacy of ORM 12741 (60 and 200 mg dosed twice daily) as an add-on therapy in patients with moderate AD with behavioral symptoms and already treated with drugs currently on the market. It was reported that, after 3 months, the patients taking ORM 12741 showed a significant improvement in memory tasks with respect to those taking placebo (Anonymous, 2016o) .
Conclusion
Further studies are warranted to enhance our knowledge of the pathology of AD and to solve the controversies of the large number of therapeutic strategies that have failed to prevent or attenuate this devastating disease. In this respect, the development and use of transgenic rodent models of AD represents a useful tool not only in resembling aspects of disease phenotypes but also in unraveling neuropathological alterations at very early stages of disease progression, which are difficult to study in AD patients. Although care is needed in the extrapolation of preclinical results to clinical practice, because of the lack of an animal model that recapitulates the full spectrum of features of AD, there is no doubt about the contribution of basic science models in the field of Alzheimer's research. Findings from preclinical studies will enhance our knowledge of the identification of molecular mechanisms implicated in the pathogenesis of AD, thus leading to the development and evaluation of promising therapeutic strategies that will hopefully translate into clinical practice in the near future.
